US 12,351,609 B2
Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
Eric N. Olson, University Park, TX (US); Rhonda S. Bassel-Duby, Dallas, TX (US); Catherine A. Makarewich, Dallas, TX (US); and Benjamin R. Nelson, Dallas, TX (US)
Assigned to The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Aug. 2, 2021, as Appl. No. 17/392,137.
Application 16/743,831 is a division of application No. 15/491,057, filed on Apr. 19, 2017, granted, now 10,570,183, issued on Feb. 25, 2020.
Application 17/392,137 is a continuation of application No. 16/743,831, filed on Jan. 15, 2020, granted, now 11,111,278.
Claims priority of provisional application 62/324,706, filed on Apr. 19, 2016.
Prior Publication US 2021/0380650 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01)
CPC C07K 14/47 (2013.01) [A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61K 48/0058 (2013.01)] 20 Claims
 
1. A polynucleotide encoding a human Dwarf open reading frame (DWORF) polypeptide consisting of the sequence of SEQ ID NO: 3, wherein the polynucleotide has at least 80% identity to SEQ ID NO: 4, and is operatively linked to a heterologous muscle-specific or cardiac-specific promoter.